MedTrace Logo

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

NCT02822495 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-06-15

No results posted yet for this study

Summary

The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and who are not eligible to enroll in clinical studies designed to support the development and registration of tabelecleucel.

Conditions

  • Epstein-Barr Virus (EBV) Infections
  • Lymphoproliferative Disorders
  • EBV+ Associated Lymphoma
  • EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
  • Epstein-Barr Viremia
  • Lymphoma, AIDS-related
  • Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID)
  • Leiomyosarcoma (LMS)
  • Nasopharyngeal Carcinoma (NPC)
  • Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID)
  • Solid Organ Transplant Complications
  • Stem Cell Transplant Complications

Interventions

BIOLOGICAL

tabelecleucel

Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Sponsors & Collaborators

Principal Investigators

  • Aditi Mehta, DO · Atara Biotherapeutics

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02822495 on ClinicalTrials.gov